Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 620. The title of the hearing was ``Legislative
Proposals to Support Patients and Caregivers.'' The
Subcommittee received testimony from:
Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Corey Feist, JD, MBA, Co-Founder and CEO,
Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and
Christina Annunziata, MD, PhD, Senior Vice
President of Extramural Discovery Science, American
Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 620, without amendment, to
the full Committee by a record vote of 26 yeas and 0 nays.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 620,
without amendment, favorably reported to the House by a record
vote of 43 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to promote
effective coordination and planning for the continued
investment in Alzheimer's disease and dementia research.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 620 is known to be duplicative of another Federal program,
including any program that was included in a report to Congress
pursuant to section 21 of Public Law 111-139 or the most recent
Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 620:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 620. The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 620 contains no earmarks, limited tax
benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the
``Alzheimer's Accountability and Investment Act''.
Section 2. Extension of project
Section 2 requires the Director of the National Institutes
of Health to prepare and submit an annual professional
judgement budget estimate for the reports and recommendations
made under the National Alzheimer's Project Act.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
NATIONAL ALZHEIMER'S PROJECT ACT
* * * * * * *
SEC. 2. THE NATIONAL ALZHEIMER'S PROJECT.
(a) Definition of Alzheimer's.--In this Act, the term
``Alzheimer's'' means Alzheimer's disease and related
dementias.
(b) Establishment.--There is established in the Office of the
Secretary of Health and Human Services the National Alzheimer's
Project (referred to in this Act as the ``Project'').
(c) Purpose of the Project.--The Secretary of Health and
Human Services, or the Secretary's designee, shall--
(1) be responsible for the creation and maintenance
of an integrated national plan to overcome Alzheimer's;
(2) provide information and coordination of
Alzheimer's research and services across all Federal
agencies;
(3) accelerate the development of treatments that
would prevent, halt, or reverse the course of
Alzheimer's;
(4) improve the--
(A) early diagnosis of Alzheimer's disease;
and
(B) coordination of the care and treatment of
citizens with Alzheimer's;
(5) ensure the inclusion of ethnic and racial
populations at higher risk for Alzheimer's or least
likely to receive care, in clinical, research, and
service efforts with the purpose of decreasing health
disparities in Alzheimer's; and
(6) coordinate with international bodies to integrate
and inform the fight against Alzheimer's globally.
(d) Duties of the Secretary.--
(1) In general.--The Secretary of Health and Human
Services, or the Secretary's designee, shall--
(A) oversee the creation and updating of the
national plan described in paragraph (2); and
(B) use discretionary authority to evaluate
all Federal programs around Alzheimer's,
including budget requests and approvals.
(2) National plan.--The Secretary of Health and Human
Services, or the Secretary's designee, shall carry out
an annual assessment of the Nation's progress in
preparing for the escalating burden of Alzheimer's,
including both implementation steps and recommendations
for priority actions based on the assessment.
(e) Advisory Council.--
(1) In general.--There is established an Advisory
Council on Alzheimer's Research, Care, and Services
(referred to in this Act as the ``Advisory Council'').
(2) Membership.--
(A) Federal members.--The Advisory Council
shall be comprised of the following experts:
(i) A designee of the Centers for
Disease Control and Prevention.
(ii) A designee of the Administration
on Aging.
(iii) A designee of the Centers for
Medicare & Medicaid Services.
(iv) A designee of the Indian Health
Service.
(v) A designee of the Office of the
Director of the National Institutes of
Health.
(vi) The Surgeon General.
(vii) A designee of the National
Science Foundation.
(viii) A designee of the Department
of Veterans Affairs.
(ix) A designee of the Food and Drug
Administration.
(x) A designee of the Agency for
Healthcare Research and Quality.
(B) Non-federal members.--In addition to the
members outlined in subparagraph (A), the
Advisory Council shall include 12 expert
members from outside the Federal Government,
which shall include--
(i) 2 Alzheimer's patient advocates;
(ii) 2 Alzheimer's caregivers;
(iii) 2 health care providers;
(iv) 2 representatives of State
health departments;
(v) 2 researchers with Alzheimer's-
related expertise in basic,
translational, clinical, or drug
development science; and
(vi) 2 voluntary health association
representatives, including a national
Alzheimer's disease organization that
has demonstrated experience in
research, care, and patient services,
and a State-based advocacy organization
that provides services to families and
professionals, including information
and referral, support groups, care
consultation, education, and safety
services.
(3) Meetings.--The Advisory Council shall meet
quarterly and such meetings shall be open to the
public.
(4) Advice.--The Advisory Council shall advise the
Secretary of Health and Human Services, or the
Secretary's designee.
(5) Annual Report.--The Advisory Council shall
provide to the Secretary of Health and Human Services,
or the Secretary's designee and Congress--
(A) an initial evaluation of all federally
funded efforts in Alzheimer's research,
clinical care, and institutional-, home-, and
community-based programs and their outcomes;
(B) initial recommendations for priority
actions to expand, eliminate, coordinate, or
condense programs based on the program's
performance, mission, and purpose;
(C) initial recommendations to--
(i) reduce the financial impact of
Alzheimer's on--
(I) Medicare and other
federally funded programs; and
(II) families living with
Alzheimer's disease; and
(ii) improve health outcomes; and
(D) annually thereafter, an evaluation of the
implementation, including outcomes, of the
recommendations, including priorities if
necessary, through an updated national plan
under subsection (d)(2).
(6) Termination.--The Advisory Council shall
terminate on December 31, 2025.
(f) Data Sharing.--Agencies both within the Department of
Health and Human Services and outside of the Department that
have data relating to Alzheimer's shall share such data with
the Secretary of Health and Human Services, or the Secretary's
designee, to enable the Secretary, or the Secretary's designee,
to complete the report described in subsection (g).
(g) Annual report.--The Secretary of Health and Human
Services, or the Secretary's designee, shall submit to
Congress--
(1) an annual report that includes an evaluation of
all federally funded efforts in Alzheimer's research,
clinical care, and institutional-, home-, and
community-based programs and their outcomes;
(2) an evaluation of all federally funded programs
based on program performance, mission, and purpose
related to Alzheimer's disease;
(3) recommendations for--
(A) priority actions based on the evaluation
conducted by the Secretary and the Advisory
Council to--
(i) reduce the financial impact of
Alzheimer's on--
(I) Medicare and other
federally funded programs; and
(II) families living with
Alzheimer's disease; and
(ii) improve health outcomes;
(B) implementation steps; and
(C) priority actions to improve the
prevention, diagnosis, treatment, care,
institutional-, home-, and community-based
programs of Alzheimer's disease for individuals
with Alzheimer's disease and their caregivers;
and
(4) an annually updated national plan.
(h) Professional Judgment Budget.--For fiscal year 2024 and
each subsequent fiscal year, the Director of the National
Institutes of Health shall prepare and submit, directly to the
President for review and transmittal to Congress, after
reasonable opportunity for comment, but without change, by the
Secretary of Health and Human Services and the Advisory
Council, an annual budget estimate for the initiatives of the
National Institutes of Health pursuant to the reports and
recommendations made under this Act, including an estimate of
the number and type of personnel needs for the National
Institutes of Health.
[(h)] (i) Sunset.--The Project shall expire on December 31,
2025.
[all]